Entero Healthcare Solutions Ltd

NSE: ENTERO BSE: 544122Pharma

Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services[1]

₹1,170

52W: ₹944 — ₹1511

PE 168 · Book ₹384 · +205% vs book

Market Cap₹5,092 Cr

Stock P/E168Price to Earnings

ROCE4.54%Return on Capital

ROE3.22%Return on Equity

Div. Yield0%Face Value ₹10

Strengths

+Company is almost debt free.
+Debtor days have improved from 124 to 89.2 days.

Weaknesses

−Stock is trading at 3.04 times its book value
−Though the company is reporting repeated profits, it is not paying out dividend
−Earnings include an other income of Rs.48.1 Cr.

Shareholding Pattern

Promoters52.42%

FIIs4.03%

DIIs16.62%

Public26.94%

Category	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	52.44%	52.44%	52.44%	52.42%▼0.0	52.42%	52.42%	52.42%	52.42%
FIIs	23.32%	23.82%▲0.5	22.2%▼1.6	19.92%▼2.3	17.21%▼2.7	14.68%▼2.5	5.14%▼9.5	4.03%▼1.1
DIIs	2.06%	7.73%▲5.7	8.78%▲1.0	9.63%▲0.9	10.19%▲0.6	9.64%▼0.5	16.42%▲6.8	16.62%▲0.2
Public	22.18%	16.02%▼6.2	16.59%▲0.6	18.03%▲1.4	20.19%▲2.2	23.26%▲3.1	26.03%▲2.8	26.94%▲0.9

Financial Statements

Metric	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	73.81	76.59	106.56	122.38	112.83	101.15	72.3	79.35	83.22	106.74
Expenses	83	85.09	115.75	124.23	118.9	111.63	84.23	93.06	95.81	120.62
Operating Profit	-9.19	-8.5	-9.19	-1.85	-6.07	-10.48	-11.93	-13.71	-12.59	-13.88
OPM %	-12.45%	-11.1%	-8.62%	-1.51%	-5.38%	-10.36%	-16.5%	-17.28%	-15.13%	-13%
Net Profit	-2.14	0.95	37.28	20.88	15.33	10.78	-27.81	6.96	5.7	0.81
EPS ₹	-1.33	0.59	8.57	4.8	3.52	2.48	-6.39	1.6	1.31	0.19

AI Insights

Revenue Trend

TTM revenue at ₹342Cr, down 16.4% YoY. OPM at -15%.

Debt Position

Borrowings at ₹28Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.

Institutional Flow

DIIs: 16.62% (+14.34pp change). FIIs: 4.03% (-19.27pp change). Promoters hold 52.42%.

Margin & Efficiency

ROCE improving from 0% (Mar 2020) to 5% (Mar 2025). Working capital days: 432.

Valuation

PE 168x with 4.54% ROCE. Price is 205% above book value of ₹384. Dividend yield: 0%.